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Abstract
Long-term vascular complications still represent the main cause of morbidity and mortality in diabetic patients. Although randomized
long-term clinical studies comparing the effects of conventional and intensive therapy have demonstrated a clear link between
hyperglycemia and the development of complications of diabetes, they have not deﬁned the mechanism through which excess glucose
results in tissue damage. Evidence has accumulated indicating that oxidative stress may play a key role in the etiology of diabetic
complications. Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential
relevance to human vascular disease. Their formation in vivo seems to reﬂect primarily, if not exclusively, a nonenzymatic process of
lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF has been described in association with both type 1 and type 2 diabetes 2a
mellitus, and correlates with impaired glycemic control. Besides providing a likely noninvasive index of lipid peroxidation in this setting,
measurements of speciﬁc F isoprostanes in urine may provide a sensitive biochemical end point for dose-ﬁnding studies of natural and 2
synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF in vitro suggest that it and other isoeicosanoids 2a
may modulate the functional consequences of lipid peroxidation in diabetes, evidence that this is likely in vivo remains inadequate at this
time. Ó 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction general population [1]. Despite this prevalence of risk
factors, no more than 25% of the excess CAD risk in
Diabetes mellitus is a major source of morbidity in diabetes can be accounted for by known risk factors [2].
developed countries and, among its comorbid conditions, Thus diabetes represents a major contributing factor to the
atherosclerosis is perhaps the most important. Since the CAD burden in the developed world, and most of the
availability of insulin, up to three fourths of all deaths excess attributed risk of CAD in diabetics cannot be
among diabetics can be directly attributed to coronary readily quantiﬁed with the use of traditional risk factor
artery disease (CAD) [1]. In adult patients with diabetes, analysis.
the risk of CAD is 3- to 5-fold greater than in nondiabetics Diabetes is associated with a variety of metabolic
despite controlling for other known CAD risk factors [1]. abnormalities, principal among which are insulin resistance
In patients with type 1 diabetes, up to one third will die of and hyperglycemia. Insulin resistance develops from obesi-
CAD by the age of 50 years [2]. A number of known risk ty and physical inactivity, acting on a substrate of genetic
factors for CAD, such as hypertension, central obesity, and susceptibility [3,4]. Insulin secretion declines with ad-
dyslipidemia, are more common in diabetics than in the vancing age [5,6], and this decline may be accelerated by
genetic factors [7,8]. Insulin resistance typically precedes
the onset of type 2 diabetes and is commonly accompanied
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been much debate as to whether or not hyperinsulinemia in AGEs may induce oxidative stress and growth factor
subjects with type 2 diabetes may increase the coronary expression, and so on. The long list is a strong indication
artery disease risk via potential adverse effects of insulin of the uncertainties in our understanding of the patho-
on the myocardium or coronary arteries due to growth genesis of diabetic complications.
stimulating effects or adverse effects on blood pressure, In this article, we will present a current perspective on
weight or lipids. In fact, CAD is often seen in subjects one of the above hypotheses, the oxidative stress hypoth-
with newly diagnosed diabetes who could not have had a esis, and will discuss the rilevance of F -isoprostanes as 2
prolonged period of hyperglycemia [11]. However, in a new markers of in vivo oxidative stress.
feasibility study of intensive therapy with insulin compared
with standard care in 153 men with type 2 diabetes on
cardiovascular events, no differences in the rate of new 2. Oxidative stress in diabetes mellitus
events were detected between groups over a 2-year follow-
up period [12]. Furthermore, the Diabetes Insulin-Glucose Among the sequelae of hyperglycemia, excess oxidative
in Acute Myocardial Infarction (DIGAMI) study [13], with stress has captured considerable attention as a potential
620 diabetic subjects, showed that intensive insulin treat- mechanism for the increased vascular disease in diabetics.
ment was associated with a lower mortality rate than The established association between atherosclerosis and
standard treatment in subjects with acute myocardial lipid peroxidation in plasma [34] and within the vascular
infarction (18.6% vs. 26.1%, P50.03). The United King- wall [35] has led to a renewed interest in the oxidative
dom Prospective Diabetes Study [14] also showed that stress of hyperglycemia as a potential mechanism for
intensive treatment with insulin or oral sulphonylureas diabetic vascular disease. Early experimental evidence
reduced the risk of myocardial infarction (15.8% vs. have supported the association between oxidative stress
18.1%, P50.052), a reduction of borderline statistical and hyperglycemia, showing that plasma from diabetic
signiﬁcance. Insulin treatment did not increase the risk of subjects contains increased levels of thiobarbituric acid-
cardiovascular disease. These studies suggest that the reactive substances [36] and lipid hydroperoxides [37], two
macrovascular complications of diabetes are more likely classic markers of lipid peroxidation.
related to the degree of prevailing hyperglycemia or its Consistent with the concept of enhanced lipid peroxida-
associated cardiovascular risk factors and are not due to tion in diabetes, Gopaul et al. [38] have reported that the
the administration of exogenous insulin. average concentration of esteriﬁed 8-iso-PGF (a major 2a
The relation between hyperglycemia and CAD is the F -isoprostane) in plasma from 39 patients with type 2 2
subject of considerable debate because serum glucose does diabetes was approximately threefold higher than in heal-
not consistently predict the existence of CAD [2,15], thy individuals. Catella-Lawson et al. [39] have reported a
especially in type 2 diabetes [15,16]. Presumably, this trend toward increased urinary 8-iso-PGF excretion in a 2a
confusion stems from the reliance on a single blood group of 18 diabetics, with statistically signiﬁcant eleva-
glucose measurement, as recent prospective data have tions in patients presenting with diabetic ketoacidosis.
clearly established a link between a marker for chronic Finally, in our recent study [40], urinary immunoreactive
average glucose levels (HbA1 ) and cardiovascular mor- 8-iso-PGF was signiﬁcantly higher in a group of 62 type C2 a
bidity and mortality [17]. There is considerable con- 2 and 23 type 1 patients than in age-matched control
troversy with respect to the precise mechanism by which subjects by approximately twofold (Fig. 1).
hyperglycemia may contribute to the development of CAD
in diabetes. A number of equally tenable hypotheses have
been suggested, including but not limited to, the Maillard, 3. Putative mechanisms of oxidative stress in diabetes
or advanced glycation end product (AGE) hypothesis
[18,19], the aldose reductase hypothesis [20], oxidative The molecular mechanism of biological oxidation by
stress [21–23], reductive stress (pseudohypoxia) [24,25], glucose was ﬁrst identiﬁed in 1912 and referred as the
true hypoxia [26], carbonyl stress [27,28], altered lipopro- ‘Maillard reaction’ [41]. The Maillard reaction accounts
tein metabolism [27,29,30], increased protein kinase C for the glucose dependent, nonenzymatic covalent modi-
activity [31], and altered growth factor [32] or cytokine ﬁcation of proteins that accompanies hyperglycemic states.
[33] activities. All of these hypotheses have strong propo- Initially, the Maillard reaction involves the combination of
nents in academe, in medicine, and in the pharmaceutical the aldehyde group of glucose in the open-chain form with
industry. The list is long, perhaps because each hypothesis amine groups on proteins to form a Schiff base followed
is a different reﬂection of an underlying common patho- by Amadori rearrangement to form fructoselysine. This
genic mechanism, or perhaps because different tissues are reversible glycosylation of amino groups, or glycation,
sensitive to different mechanisms. The various hypotheses underlies the formation of HbA , the well-recognized 1C
overlap and intersect with one another: AGE formation and marker of chronic glycemic control in diabetes mellitus,
altered polyol pathway activity may lead to oxidative and is not of any direct pathophysiological signiﬁcance for
stress, oxidative stress may accelerate AGE formation, the complications of diabetes. By contrast, the ﬁnal stage
reductive stress may lead to activation of protein kinase C, of the Maillard reaction involves the irreversible oxidation,
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the most direct is the autoxidation of glucose. Monosac-
charides with an a-hydroxyaldehyde structure, like glu-
cose, are subject to enediol rearrangement that results in
the formation of an enediol radical ion [43]. The formation
of this radical anion has two important implications. First,
this species is capable of reduced molecular oxygen to
form superoxide anion which, under certain circumstances,
may contribute to the oxidation of lipids [44] or the
activation of platelets [45]. Second, the dicarbonyl prod-
ucts formed by this pathway are quite reactive and may
modify adjacent lysine groups to form AGEs such as
« N -(carboxymethyl)lysine directly. These reactions derived
from glucose enolization are, however, dependent on
transition metal ions [43], and the availability of free,
redox-active transition metal ions in vivo is controversial.
Recent data demonstrating glycation-induced ceruloplas-
min fragmentation and free copper release offer one
possible mechanism for a source of extracellular transition
metals [46]. As an alternative mechanism of AGE-me-
diated oxidative stress, AGEs have also been shown to
induce cellular lipid peroxidation through interacting with
their speciﬁc surface receptor (RAGE) [47], and this effect
can be attenuated by vitamin E [48]. Regardless of the
mechanism for the synthesis of AGEs, several features of
AGE action can have direct inﬂuence on the progression of
atherosclerosis. In fact, in addition to their role in lipid
peroxidation, AGEs enhance the aggregation of human
platelets ex vivo [49]. Moreover, AGE-modiﬁed albumin
has also been shown to induce monocyte tissue factor
expression and procoagulant activity [50]. Thus, AGE
formation on proteins and lipids appears to contribute to
both lipid peroxidation and platelet activation and may
therefore contribute to the rapid progression of CAD in
diabetic patients.
One interesting point raised by several studies is the
enzyme(s) responsible for free radical production in arterial
vessel. NADH oxidase has been proposed to be a major
2 source of superoxide anion (O ) in normal and diseased 2
blood vessels [51]. To test this hypothesis, Lund et al. [52]
2 assessed O production in vessels from normal or diabetic 2 Fig. 1. Urinary excretion rates of 8-iso-PGF in 62 patients with type 2 2a rabbits that were stimulated by NADH oxidase. Superox- (upper panel) and 23 type 1 (lower panel) diabetes and matched healthy
ide production in response to NADH was .2-fold greater subjects. Dots represent individual measurements; horizontal bars repre-
` in carotid arteries from diabetic rabbits than in normal sent mean value for each group (published by the permission of Davı et
al., Circulation 1999;99:224–229). carotids. These data suggest increased propensity to gener-
2 ate O levels in arterial vessels from diabetic animals 2
or glycoxidation, of fructoselysine to yield a host of during treatment with NADH. Because numerous studies
advanced glycation end products (AGEs) such as W-(car- suggest that the mechanism of impaired endothelium-de-
boxymethyl)lysine, pentosidine, and pyrroline, the forma- pendent relaxation in diabetes may involve inactivation of
tion of which correlates directly with the vascular and nitric oxide (NO) by oxygen-derived free radicals [53,54],
renal complications of diabetes mellitus [42]. These carbo- increased activity of NAD/NADH oxidase in diabetic
hydrate-derived protein oxidation products are readily vessel could play a pivotal role in the early stage of
quantiﬁed with gas chromatography/mass spectroscopy vascular complications in diabetes.
and are more abundant in diabetics than in age-matched In tissues where glucose uptake is independent of
control subjects [42]. insulin, including retina, lens, kidney, and peripheral
In addition to AGE formation by oxidation of fruc- nerves, all tissue sites of diabetic complications, exposure
toselysine, there are a number of other putative mecha- to elevated glucose levels causes an increase in intracellu-
nisms that link hyperglycemia to oxidative stress. Among lar sorbitol and fructose levels due to increased activity of
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aldose reductase (AR) and sorbitol dehydrogenase (SDH) Recently F isoprostanes, a novel class of prostanoid-like 2
[55]. These two enzymes constitute the polyol pathway. compounds has been described by Morrow and Roberts
Increased substrate ﬂux through the polyol pathway not [64]. F isoprostanes are a family of Prostaglandin (PG) 2
only increases cellular levels of sorbitol and fructose but F isomers (Fig. 2) ﬁrst described as products of 2a
1 also decreases the ratio of NADPH to NADP and noncyclooxygenase oxidative modiﬁcations of arachidonic
1 increases the cytosolic NADH-to-NAD ratio [56]. acid that have resulted from free-radical attack of cell
The depletion of NADPH cell stores by AR may inhibit membrane phospholipids [65] or circulating LDLs [66]. In
the activity of other NADPH-requiring enzymes. This contrast to classic prostaglandins, which are formed
possibility is supported by the ﬁnding that human umbili- through the action of PGH synthase isozymes from free
cal vein endothelial cells exposed to 33 mmol/l glucose arachidonic acid [67], F isoprostanes are formed in situ 2
show a 42% decrease in NADPH concentration and a 34% from the fatty acid backbone esteriﬁed in membrane
reduction of glutathione release into the medium [57]. phospholipids. Isoprostanes maybe formed by either of two
Moreover, the same endothelial cells cultured under con- routes of peroxidation [68,69], an endoperoxide mecha-
ditions of high glucose and oxidative stress (200 mmol/l nism (Fig. 2, upper panel) or a dioxetane/endoperoxide
H O ) reduce the supply of NADPH to various NADPH- mechanism (Fig. 2, lower panel). In the former, the ﬁrst 22
dependent pathways, including the reduced glutathione oxygen molecule is incorporated into the endoperoxide
redox cycle [58]. Decreased levels of reduced glutathione ring to form the two hydroxyl groups on the PGF ring. In
increase both the susceptibility of endothelial cells to the latter, by contrast, it is the second oxygen molecule
damage by H O [57] and the cytotoxicity by a xenobiotic that is incorporated into the PGF ring. Also 5- and 15- 22
(1-chloro-2,4-dinitrobenzene) in K502 cells that possess hydroperoxy radicals can only form Groups VI and III by
characteristics for erythroid cells [59]. On the other hand, the dioxetane/endoperoxide mechanism. The radical at
there is no direct proof that tissue levels of NADPH are position 10 of arachidonic acid, by contrast, can yield
depleted in vivo in diabetes. isoprostanes by both mechanisms. Thus, hydroperoxy
The hyperglycemia-induced increase in the NADH-to- radicals formed at 8 and 12 have the option to proceed to
1 NAD ratio is referred to as hyperglycemic pseudohypoxia form a dioxetane ring (Fig. 2, upper panel) or a dioxy-
[56] and is thought to play a role in diabetic complications. pentane ring (Fig. 2, lower panel) on a competitive basis,
Part of this idea is based on similarities existing between although it is not yet clear which is favored. Recent
the metabolic consequences of pseudohypoxia (raised attention has focused upon Group VI isoprostanes. These
1 NADH-to-NAD ratio) and true hypoxia. Impaired blood compounds may be derived from a 9-hydroperoxy radical
ﬂow leading to ischemia has been noted in tissues exposed by the endoperoxide mechanism or from a 5-hydroperoxy
to diabetic complications, such as nerve, which may radical by the dioxetane/endoperoxide mechanism. How-
explain the beneﬁt of hyperbaric oxygen [60]. Both true ever, both are derived from an initial hydrogen atom
hypoxia and pseudohypoxia may generate free radicals: the abstraction at position 7 of arachidonic acid. Abstraction at
latter via an increased synthesis of prostaglandin H from carbon 13 can give rise to 11- and 15-hydroperoxy 2
prostaglandin G as the enzyme hydroperoxidase uses radicals, yielding only one series (Group III) of iso- 2
NADH as cofactor [61], the former via ischemia/reperfu- prostanes. A radical at position 10 of arachidonic acid
sion injury [62]. A vicious cycle might be envisaged in gives a radical at 8 and 12, which yields groups V and IV,
which free radicals are both cause and consequence, at respectively. If the dioxetane mechanism is operative, the
least in part, of ischemia. same 8- and 12-hydroperoxy radicals will yield Groups IV
Because of mutual facilitatory interactions between the and V, respectively. After their formation, isoprostanes are
main mediators of hyperglycemic damage to tissues (poly- released from the membrane phospholipids in response to
ol pathway, oxidative stress, AGEs, prostanoid metabo- cellular activation, presumably through a phospholipase-
lism), it is not surprising that correction of any of them mediated mechanism; they circulate in plasma and are
may result in amelioration of endothelium-dependent excreted in the urine [70,71]. They may circulate as the
vasodilatation. In experimental diabetic neuropathy, for free form or as esters in phospholipids in plasma. The
example, aminoguanidine, inhibitors of AR, and antioxi- factors that regulate release of endogenous isoprostanes
dants are all effective in ameliorating or preventing early from cell membranes and interconversion between the free
neurovascular dysfunction [63]. and esteriﬁed forms are presently poorly understood. It is
conjecturable that hyperglycemia could inﬂuence the re-
lease of isoprostanes from cell membranes via increased
4. Isoprostanes as new markers of in vivo lipid activation of protein kinase C and phospholipase A . 2
peroxidation Given the ubiquitous distribution of the precursor arach-
idonic acid, isoprostane biosynthesis can occur in virtually
Unlike the quantitation of AGEs and AGE-modiﬁed all of the cellular players of the atherosclerotic lesion,
proteins, the quantitation of lipid peroxidation in the including monocytes [72]. Indeed, coincubation of acti-
setting of hyperglycemia has been more problematic. vated human monocytes with LDL resulted in a time-
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
7
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 A. Mezzetti et al. / Cardiovascular Research 47 (2000) 475–488 479
Fig. 2. Formation of four types of isoprostanes by the two routes of peroxidation, an endoperoxide (upper panel) or dioxetane/endoperoxide (lower panel)
mechanism (modiﬁed from Lawson JA. et al., J Biol Chem 1999;274:24441–24444).
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dependent formation of the F isoprostane 8-iso-prostag- 12-epi-PGF , activates PGF receptors and stimulates 22 a 2a
landin (PG) F (also referred to as iPF -III [73]), but not proliferative responses in ﬁbroblasts [81]. 2a 2a
of PGE or thromboxane (TX) B , coincident with LDL Formation of isoprostanes in situ in the phospholipid 22
oxidation [72]. The increase in 8-iso-PGF formation was bilayer may modify cellular function. Subsequent cleavage 2a
associated with an increase in thiobarbituric acid-reactive may release products, such as 8-iso-PGF , that modify 2a
substance (TBARS) and hydroperoxide levels. This phe- aspects of platelet function such as adhesive reactions and
nomenon was prevented by the oxygen free-radical scaven- activation by low concentrations of other agonists. Forma-
gers superoxide dismutase (SOD) and butylhydroxytoluene tion of isoprostanes in monocytes may modify aspects of
(BHT) but not by cyclooxygenase inhibitors [72]. Con- their function, such as expression of tissue factor [82].
sistent with these in vitro studies, immunolocalization of Similarly, formation of isoprostanes in oxidized LDL may
8-iso-PGF in the monocytes/macrophages and vascular result in their uptake by macrophages, resulting in the 2a
smooth muscle cells of human atherosclerotic tissue has formation of foam cells. Isoprostanes may also modify
recently been described in specimens obtained during vascular smooth muscle cell function and accumulate in
carotid endarterectomy [74]. these cells in proximity to atherosclerotic plaques (Fig. 3).
In addition to a cyclooxygenase-independent mechanism Concentration of 8-iso-PGF in the range of 1 nmol/l 2a
of formation involving peroxidative attack on arachidonic to 1 mmol/l induces a dose-dependent increase in platelet
acid, in which bicyclic endoperoxide intermediates are shape change, calcium release from intracellular stores,
formed that are then reduced to give rise to isoprostanes and inositol phosphates [80,83]. Moreover, 8-iso-PGF2a
such as 8-iso-PGF , there is recent evidence that 8-iso- causes dose-dependent, irreversible platelet aggregation in 2a
PGF , unlike other F isoprostanes, can be produced as a the presence of concentrations of collagen, ADP, arach- 2a 2
minor product of the cyclooxygenase activity of platelet idonic acid, and PGH /TXA analogues that, when acting 22
PGH synthase-1 in response to platelet stimulation with alone, fail to aggregate platelets [80]. These effects are
collagen, thrombin, or arachidonate [71,75]. Activated prevented by PGH /TXA receptor antagonists and 8-iso- 22
platelets can generate 8-iso-PGF and TXB in a molar PGF may cross-desensitize biochemical and functional 2a 22 a
ratio of |1:1000 [71,75]. A second enzyme endowed with responses to thromboxane mimetics [84,85]. Moreover,
cyclooxygenase activity, PGH synthase-2, can be ex- recent evidences based on genetically modiﬁed mice have
pressed in different cell types in response to inﬂammatory conﬁrmed that the effects of bioactive isoprostanes 8-iso-
and mitogenic stimuli (reviewed in Reference [67]). Induc- PGF and iPE -III on vascular tone and platelet function 2a 2
tion of PGH synthase-2 in human monocytes by con- are transduced via activation of the thromboxane A2
canavalin A, phorbol ester, or bacterial lipopolysaccharide receptor in vivo in the mouse and do not depend on the
was associated with cyclooxygenase-dependent formation existence of related, but distinct isoprostane receptors [86].
of 8-iso-PGF and PGE in a molar ratio ranging from Thus, although 8-iso-PGF fails to activate either of the 2a 2 2a
1:5 to 1:30 [72,76]. Dexamethasone, an inhibitor of PGH TX receptor isoforms described in platelet at concen-
synthase-2 induction, and L-745337, a selective inhibitor trations that typically circulate during syndromes of oxid-
of the cyclooxygenase activity of monocyte PGH synthase- ant stress [80], evidences suggesting a distinct receptor for
2 [77], dose-dependently suppressed 8-iso-PGF and this molecule are inconclusive. Furthermore, although 2a
PGE formation with similar potency [72,76]. However, isoprostanes may act as incidental ligands for prostanoid 2
the contribution of cyclooxygenase-dependent mechanisms receptors, their effects may differ from the cognate ligand.
to the formation of 8-iso-PGF in vivo appears to be For example, 8,12-iso-iPF -III, which ligates the PGF 2a 2a 2a
negligible [71], and the general assumption that measure- receptor and causes a hypertrophic response in car-
ments of this F -isoprostane in plasma or urine are a diomyocytes, activates distinct as well as overlapping 2
reﬂection of nonenzymatic lipid peroxidation has been downstream signaling pathways when compared with
validated in clinical settings of platelet and/or monocyte PGF [87]. 2a
activation (see below). Whether the local concentrations of isoprostanes
achieved in vivo are sufﬁcient to allow them to act as a
ligand for prostanoid receptors remains unclear. However,
5. Biological effects of isoprostanes the ability of 8-iso-PGF to amplify the aggregation 2a
response to subthreshold concentrations of platelet agonists
Several isoprostanes are known to have biological might be relevant to setting, such as diabetes mellitus,
effects in vitro via membrane receptors for prostaglandins. where persistent platelet activation and enhanced free-
Their formation in lipid bilayers by a free radical-catalyzed radical formation coincide. In fact, diabetes is character-
mechanism may contribute importantly to alterations in the ized by platelet activation in vivo, as reﬂected by enhanced
ﬂuidity and integrity of cellular membranes. In addition, thromboxane metabolite excretion [88]. Immunoreactive
8-iso-PGF is a potent vasoconstrictor [78] and induces 8-iso-PGF is altered in patients with diabetes and 2a 2a
DNA synthesis in vascular smooth muscle cells, through appears to contribute to platelet activation in this setting
interaction with TXA receptor [79] or perhaps with [40]. Paired urinary measurements of 8-iso-PGF and 2 2a
speciﬁc receptors [80]. Similarly, another F isoprostane 11-dehydro-TXB (a major metabolite of TXA ) in dia- 22 2
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Fig. 3. Potential sites of isoprostane formation and cellular targets of 8-iso-PGF of relevance to atherothrombosis. ELAM indicates endothelial leukocyte 2a
adhesion molecule; PGI , prostacyclin; PAF, platelet-activating factor; TX, thromboxane; and VCAM, vascular cell adhesion molecule (published by the 2
permission of Patrono et al., Arterioscler Thromb Vasc Biol 1997;17:2309–2315).
betic patients revealed a highly signiﬁcant linear correla- glycemia both above and below the threshold for diabetes
tion between the two. Urinary immunoreactive 8-iso- and cardiovascular risk, proof that hyperglygemia causes
PGF was unchanged following a 2-week dosing with CAD was for long time less convincing. Establishing a 2a
aspirin or indobufen, a reversible cyclooxygenase inhibitor, causal link between hyperglycemia and CAD is likely to
despite complete suppression of thromboxane metabolite be difﬁcult given that both are complex conditions. Re-
excretion, indicating that the oxidative stress in diabetics is cently, it has been provided an important ﬁrst step in
likely to be a cause and not a consequence of platelet understanding the implications of hyperglycemia-induced
activation [40]. Consistent with the hypothesis of enhanced lipid peroxidation and increased production of 8-iso-PGF2a
8-iso-PGF formation’s contribution to platelet activation in diabetic vascular disease [40]. Using a speciﬁc radioim- 2a
in this setting, dose-dependent suppression of the former munoassay, it has been found that urinary excretion of
by vitamin E supplementation was associated with compar- 8-iso-PGF in diabetic patients was essentially twice that 2a
able reductions in 11-dehydro-TXB excretion. Thus, of healthy age-matched control subjects (Fig. 1). With 2
enhanced nonenzymatic peroxidation of arachidonic acid regard to urinary 8-iso-PGF excretion, similar ﬁndings 2a
may provide a biochemical link between oxidant stress and were observed both for type 2 and type 1 diabetic patients
platelet activation in the setting of diabetes mellitus. [40] (Fig. 1). These concordant observations between type
The studies of 8-iso-PGF formation conducted so far 2 and type 1 diabetic patients would tend to implicate 2a
appear to exclude a signiﬁcant contribution from a cyclo- hyperglycemia as the culprit metabolic derangement, since
oxygenase-dependent mechanism of biosynthesis in vivo. this is a major common feature of both patient populations.
This is particularly supported by no effects of aspirin and Consistent with this notion, we have reported that im-
other nonspeciﬁc cyclooxygenase inhibitors on urinary proved metabolic control of type 2 diabetic patients
8-iso-PGF in diabetic patients. The availability of selec- signiﬁcantly reduced urinary 8-iso-PGF levels by 32% 2a 2a
tive inhibitors of PGH synthase-2 will permit further [40] (Fig. 4). Furthermore, reports that improved glycemic
deﬁnition of the potential contribution of this pathway to control by pancreatic islet transplantation reduces vascular
formation of 8-iso-PGF , particularly in the setting of oxidative stress and reverses antioxidant enzyme upregula- 2a
complicated diabetes, were induction of this enzyme might tion in rats with streptozotocin-induced diabetes are con-
be anticipated. sistent with hyperglycemia as a source of oxidative stress
[89]. This increase in 8-iso-PGF was signiﬁcantly corre- 2a
lated with blood glucose and increased platelet activation.
6. Hyperglycemia and isoprostane generation On the basis of prior studies indicating that 8-iso-PGF2a
ampliﬁes agonist-induced platelet aggregation [80], these
It is debated if hyperglycemia per se is causally related results strongly suggest that increased lipid peroxidation in
to cardiovascular disease or is merely a marker for some diabetic patients leads to the formation of 8-iso-PGF , 2a
underlying factor that causes both diabetes and CAD. which, in turn, leads to platelet activation. In support of
While there is a deﬁnite association between the level of this hypothesis, the reduction of 8-epi-PGF formation 2a
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interventional studies and for dose selection for antioxi-
dants employed in such clinical trials [93].
A limited number of studies have been completed during
the past 5 years addressing the formation of F iso- 2
prostanes in clinical settings putatively associated with
oxidative damage, often as a result of long-standing
metabolic abnormalities.
Persistently enhanced formation of F -isoprostanes has 2
been reported in association with several clinical con-
ditions, including diabetes mellitus [38–40], hypercholes-
terolemia [94,95], coronary ischemia-reperfusion
syndromes [96,97], unstable angina [98], chronic obstruc-
tive pulmonary disease [99], cystic ﬁbrosis [100] and
cigarette smoking [101,102], conditions putatively char-
acterized by increased lipid peroxidation in response to the
complex metabolic abnormalities or various constituents of
cigarette smoke. Accelerated LDL oxidation [103] as well
as platelet activation [104], are common features of these
conditions.
Although diabetes mellitus is a clearly established risk
factor for cardiovascular disease, the mechanism(s) respon- Fig. 4. Changes in F -isoprostane formation associated with improved 2
metabolic control in type 2 diabetes. Individual measurements of 8-iso- sible for accelerated atherogenesis remain elusive. Altered
PGF excretion are represented for 17 patients who achieved improved 2a lipoprotein levels; changes in lipoprotein composition,
metabolic control (ie, blood glucose,200 mg/dL and HbA ,9%) after 1c possibly affecting LDL binding to its receptors; and ` intensive monitoring and treatment (published by the permission of Davı
reduced LDL clearance resulting from impaired receptor et al., Circulation 1999;99:224–229).
recognition of glycated LDL have been described in
diabetic patients (reviewed in Reference [105]). Moreover,
through improved metabolic control also reduced platelet both high glucose levels and protein glycation enhance
activation [40]. Taken together, these data suggest that the LDL oxidation by metal ions, and these reactions also
extent of metabolic control has a profound inﬂuence on the yield advanced glycosilation end (AGE) products
degree of oxidative stress and platelet activation in patients [103,105]. In fact, LDLs isolated from type 2 diabetics
with diabetes. contain higher levels of AGE products and conjugated
Whether F -isoprostanes can also inﬂuence insulin dienes and are more easily oxidized by copper than native 2
resistance in diabetic patients is presently poorly under- LDL [106]. In addition, plasma from patients whose type 1
stood. Recently, Laight et al. [90] have investigated diabetes mellitus is poorly controlled has less antioxidant
oxidant stress, glucose tolerance and glucose-stimulated capacity [107]. Oxidatively modiﬁed LDL has been found
insulin responses in the obese Zucker rat, a widely used in foam cells and atherosclerotic plaques and has been
model of insulin resistance. The plasma level of 8-iso- shown to acquire a variety of properties possibly relevant
PGF was elevated approximately 5-fold in old obese to the process of atherogenesis [35,108]. 2a
relative to age-matched, insulin-sensitive. Supplementation When LDL is oxidized in vitro, either by exposure to
of the diet with vitamin E reduced plasma 8-iso-PGF and copper or by coincubation with endothelial cells, iso- 2a
concomitantly reversed glucose-stimulated hyperin- prostanes are formed in a time-dependent manner, along
sulinemia in this experimental model. This could explain, with more conventional indices of lipid peroxidation
at least in part, the beneﬁcial effects of antioxidants on [66,109,110]. However, it is unknown how oxidizability of
insulin action previously reported in literature [91]. How- LDL, either in vitro or ex vivo, relates to actual LDL
ever, whether 8-iso-PGF plays a pivotal role also in oxidation in vivo. Isoprostanes are present in human 2a
patients with hyperinsulinemia and insulin resistance but atherosclerotic plaque [74,111], as are isoeicosatrienoic
without overt hyperglycemia is still unclear at this time. acids, which appear to be even more abundant [112].
Formation of isoprostanes in monocytes/macrophages in
atherosclerotic plaques may modify aspects of their func-
7. Potential role of isoprostanes in atherosclerosis tion, such as expression of tissue factor [82]. Moreover,
formation of isoprostanes in oxidized LDL results in their
Given the abundant information that oxidation of LDL uptake by monocytes/macrophages, resulting in the forma-
confers properties thought relevant to atherogenesis [92], tion of foam cells. Finally, isoprostanes may also accumu-
there has been interest in the potential of isoprostane late in vascular smooth muscle cell in atherosclerotic
measurements both to identify patient populations for plaques (Fig. 3). Thus, although a functional role for
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isoprostanes in atherogenesis remains to be established, optimal dose of vitamin E supplementation, largely be-
discriminant production of isoprostanes by both reactive cause of inadequate biological end points for its efﬁcacy.
oxygen species and monocyte PGH synthase 2 within This is reﬂected in a wide range of vitamin E doses tested
atherosclerotic plaques renders it a candidate molecule to in randomized clinical trials, from as low as 50 mg daily to
transduce, at least in part, the effects of lipid peroxidation as high as |500 mg daily [115–117], and in a broad
and inﬂammation on vascular dysfunction. spectrum of clinical beneﬁts, from a 60% reduction in
` To address this hypothesis, Pratico et al. [113] have nonfatal myocardial infarction in the CHAOS study [116]
recently studied isoprostane generation before and after to the absence of beneﬁts in the recent HOPE trial [117]. A
vitamin E supplementation in the hypercholesterolemic, number of mechanisms have been suggested to contribute
ApoE-deﬁcient mouse that develops atherosclerosis-type to the putative beneﬁcial effects of vitamin E, including
lesions on a chow diet. Supplementation with vitamin E inhibition of LDL oxidation and prevention of fatty streak
signiﬁcantly reduced isoprostane generation, but had not formation, stabilization of coronary lesions, a direct anti-
effect on plasma cholesterol levels in apoE knock-out platelet effect, or improvement of endothelium-dependent
mice. This intervention also suppressed the elevated levels vasodilatation.
of iPF -VI esteriﬁed in LDL and in vascular tissue and Limited information is available on the effects of 2a
retarded the development of atherosclerosis, despite persis- vitamin E on F isoprostane formation. Thus, Reilly et al. 2
tent hypercholesterolemia [113]. [102] have reported no signiﬁcant changes in urinary
Despite these observations, it is difﬁcult to relate the 8-iso-PGF excretion following a 5-day course of vitamin 2a
concentrations of isoprostanes used to evoke biological E supplementation in a limited number of moderate (100
effects in vitro to what might pertain in vivo. First, a U/d) or heavy (800 U/d) smokers. In contrast, vitamin C
myriad of products is formed under conditions of oxidant (2 g/d) alone or in combination with vitamin E sig-
stress, and yet, to date, studies have concentrated on single niﬁcantly depressed urinary 8-iso-PGF in heavy smokers 2a
isomers. Second, these compounds may be subject to rapid to a comparable level achieved by smoking cessation
reesteriﬁcation after release from membrane phospholipids. [102]. Similarly, we found that supplementation with
Finally, the mechanisms and regulation of their release are vitamin E up to 1200 mg did not signiﬁcantly affect the
poorly understood. Nonetheless, there are hints that they urinary excretion of 8-iso-PGF in chronic smokers [118]. 2a
might have some relevance in vivo. A thromboxane In contrast, two-week dosing with vitamin E (100 to 600
receptor antagonist is more effective at preventing platelet- mg daily) was found to reduce immunoreactive 8-iso-
dependent coronary occlusion in dogs after thrombolysis PGF excretion in a dose-dependent fashion in type 2 2a
than aspirin, despite complete inhibition of thromboxane diabetic subjects, with all measurements failing within the
formation by the latter [114]. This observation suggests range of healthy subjects at 600 mg daily [40].
activation of the thromboxane receptor by a ligand distinct Failure of vitamin E supplementation to reduce throm-
from TXA and 8-iso-PGF is known to increase during boxane metabolite excretion in healthy cigarette smokers 22 a
coronary reperfusion in this model [96]. Moreover, in [118] provides important support to the contention [40,94]
patients with unstable angina, roughly 50% of the in- that vitamin E may blunt F -isoprostane-mediated ampliﬁ- 2
dividual variation in aspirin-insensitive TXA biosynthesis cation of platelet activation in several pathological clinical 2
could be accounted for by the individual variation in setting, such as those depicted in Fig. 5, rather than
8-iso-PGF formation [98]. Finally, vitamin E suppresses exerting a direct antiplatelet effect. 2a
not only 8-iso-PGF in patients with diabetes but also the The overall picture emerging from a series of studies of 2a
elevated levels of a thromboxane metabolite [40]. Perhaps, vitamin E supplementation using the in vivo formation of
as suggested above, platelet active isoprostanes, such as F isoprostane as the primary biochemical end-point 2
8-iso-PGF , contribute to the enhanced platelet activation [40,94,102,113,118] suggests that the effect of vitamin E 2a
in diabetic patients at risk of cardiovascular events. on lipid peroxidation can not be equated to that of a
conventional drug blocking an enzyme or receptor in a
reproducible fashion in the vast majority of patients
8. Effects of antioxidants exposed to treatment. Most likely, both the mechanism(s)
responsible for enhanced oxidant stress and the rate of
Numerous epidemiological studies have shown that lipid peroxidation are important determinants of the anti-
dietary intake of vitamin E is inversely associated with the oxidant effects of vitamin E supplementation. This hypoth-
risk of cardiovascular disease, though randomized inter- esis may help interpreting the conﬂicting and largely
vention trials have uncertain proved the cardiovascular disappointing results of recently completed trials of vita-
beneﬁt from vitamin treatment [115]. In general, the min E supplementation in patients with ischemic heart
epidemiological studies have been interpreted to suggest disease [116,117,119]. Any protective effect of antioxidant
that prevention of cardiovascular disease requires large intervention, that is readily apparent in the setting of
amounts of vitamin E, in excess of the conventional dietary genetically determined enhanced lipid peroxidation [113],
intake. However, there is substantial uncertainty as to the is likely to be diluted by inclusion of a large proportion of
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Fig. 5. (Panel A) Changes in plasma vitamin E levels and urinary excretion of 8-iso-PGF excretion associated with vitamin E supplementation (600 2a
mg/day for 2 weeks) in patients type 2 diabetes mellitus (NIDDM: Ref. [40]), hypercholesterolemia (HC: Ref. [94]), cystic ﬁbrosis (Ref. [100]) and in
healthy cigarette smokers (Ref. [118]). Each solid line connects mean (6S.E.M.) values measured before and after vitamin E supplementation. (Panel B)
The slope of these lines is linearly correlated with the mean basal rate of 8-iso-PGF excretion in each clinical setting (r50.976, P50.023) (published by 2a
the permission of Patrignani et al., Circulation, in press).
patients with low levels of lipid peroxidation because of sensitive biochemical end-points for dose-ﬁndings studies
dietary habits (such as in the GISSI-Prevenzione Study of natural and synthetic inhibitors of lipid peroxidation.
carried out in the setting of a largely Mediterranean diet: Although the biological effects of 8-iso-PGF in vitro 2a
Ref. [119]) or lack of metabolic abnormalities associated suggest that it and other isoeicosanoids [120,121] may
with oxidant stress. modulate the functional consequences of lipid peroxidation
Thus, F isoprostanes may have practical implications in diabetes, evidences that this is likely in vivo are growing 2
for the use of vitamin E supplements for cardiovascular but are not yet conclusive at this time.
prevention in diabetic patients, and may help to resolve
some of the uncertainty about the optimal dose of vitamin
E supplementation. Moreover, present evidences suggest Acknowledgements
the need to re-evaluate the response of potential target
populations based on non-invasive measurements of F We are indebted to Dr. Carlo Patrono for helpful 2
isoprostane formation as a rationale basis for new large- suggestions in the preparation of the manuscript.
scale interventional trial design.
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